LN6223147
LOXO-195 , 98% , 1350884-56-8
CAS NO.：1350884-56-8
Empirical Formula: C20H21FN6O
Molecular Weight: 380.42
MDL number: MFCD31620755
| Pack Size | Price | Stock | Quantity |
| 5mg | RMB1038.40 | In Stock |
|
| 10mg | RMB1838.40 | In Stock |
|
| 25mg | RMB3598.40 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| Density | 1.51±0.1 g/cm3(Predicted) |
| pka | 11.44±0.40(Predicted) |
| InChI | InChI=1S/C20H21FN6O/c1-12-4-5-16-14(9-13(21)10-22-16)17-3-2-7-26(17)18-6-8-27-19(25-18)15(11-23-27)20(28)24-12/h6,8-12,17H,2-5,7H2,1H3,(H,24,28)/t12?,17-/m1/s1 |
| InChIKey | OEBIHOVSAMBXIB-RGUGMKFQSA-N |
| SMILES | N12CCC[C@]1([H])C1=CC(F)=CN=C1CCC(C)NC(=O)C1C=NN3C=CC2=NC=13 |
Description and Uses
LOXO-195 is an orally available, highly potent, and selective TRK kinase inhibitor designed to overcome drug resistance mediated by acquired mutations. Although responses to TRK inhibition can be dramatic and durable; however, eventually emergence of acquired resistance is found to be inevitable.
(3aR)-Selitrectinib ((3aR)-LOXO-195) is an isform of Selitrectinib (HY-101977), which is a next-generation TRK kinase inhibitor, with IC50s of 0.6 nM and <2.5 nM for TRKA and TRKC, respectively[1].
